Trial intelligence / Profile preview

ZODIAC: Denosumab vs Zoledronic acid for erosive hand osteoarthritis in patients with osteoporosis

2026-526828-41-00Phase 2Authorised

Sponsor: Azienda Ospedaliera Universitaria Integrata Verona
Start: Aug 2026
Modality: Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 2, randomised trial of obodence and zoledronic acid in erosive hand osteoarthritis (EHOA) and osteoporosis (2 arms), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in total erosion volume at 12 months. Planned start Aug 2026; status: authorised.

Drugs

obodencezoledronic acid

Conditions

erosive hand osteoarthritis (EHOA)osteoporosis

Beyond the preview

Go deeper on 2026-526828-41-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-526828-41-00.